

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.ejconline.com](http://www.ejconline.com)

# A population-based study on the familial aggregation of cutaneous malignant melanoma in Iceland

Bjarki Jonsson Eldon<sup>a</sup>, Steinunn Thorlacius<sup>a</sup>, Thorvaldur Jonsson<sup>b,c</sup>,  
Jon Gunnlaugur Jonasson<sup>b,c,d</sup>, Jens Kjartansson<sup>b</sup>, Sigurdur Bodvarsson<sup>b</sup>,  
Eirikur Steingrimsen<sup>a,c</sup>, Thorunn Rafnar<sup>a,\*</sup>

<sup>a</sup>Iceland Genomics Corporation, Snorrabraut 60, 105 Reykjavik, Iceland

<sup>b</sup>Landspítali University Hospital, 101 Reykjavik, Iceland

<sup>c</sup>Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland

<sup>d</sup>Icelandic Cancer Registry, Skogarhlid 8, 105 Reykjavik, Iceland

## ARTICLE INFO

### Article history:

Received 6 October 2005

Received in revised form

16 November 2005

Accepted 21 November 2005

Available online 10 March 2006

### Keywords:

Malignant melanoma

Familial aggregation

Risk ratio

Iceland

## ABSTRACT

The aim of this study was to characterize the familial nature of cutaneous malignant melanoma (CMM) in Iceland. Risk ratio was used to estimate the risk among relatives of all CMM index cases diagnosed in Iceland over a 45-year period (1955–1999), using data from the National Cancer Registry and a genealogy database that covers the whole of Iceland's population. First-, second-, and third-degree relatives of CMM patients did not have an increased risk of the disease, and no added risk of other types of cancer among relatives was observed, except for thyroid cancer in first-degree male relatives. Seven individuals were diagnosed with two or more primary CMM in this period; none of these individuals had a first or second-degree relative with CMM. Altogether, 2.4% of cases were familial, as defined by commonly used criteria. In conclusion, high-penetrance susceptibility genes do not contribute much to CMM in the Icelandic population. The great majority of CMM cases in Iceland are most likely caused by the interplay between environmental causes and low-risk genes.

© 2006 Elsevier Ltd. All rights reserved.

## 1. Introduction

Although the development of cutaneous malignant melanoma (CMM) is strongly associated with environmental factors, genetic factors also contribute to CMM predisposition. About 8–14% of melanoma patients have a family history of the disease, defined as at least one first-degree relative with melanoma.<sup>1</sup> Population-based studies in Utah and Sweden have reported approximately 2- and 3-fold increased risk of melanoma, respectively, in first-degree relatives of melanoma probands.<sup>2–4</sup> Melanoma has also been associated with cancers of the nervous system, breast and other skin cancers.<sup>2,5</sup>

Linkage analysis of families with multiple cases of melanoma have identified inherited mutations in two genes, the cell-cycle regulator *CDKN2A*,<sup>6</sup> and the cyclin-dependent kinase-4 (*CDK4*).<sup>7</sup> The frequency of *CDKN2A* mutations was estimated at approximately 20% when multiple studies of familial melanoma kindreds from North America, Europe and Australasia were analyzed.<sup>8</sup> In contrast, a recent study by Begg and colleagues found only 65 mutation carriers among 3550 incident case patients (1.8%) from nine different geographic regions.<sup>9</sup> This study also estimated the risk of mutation carriers to be 14% by age 50 years and 28% by age 80 years.<sup>9</sup> The penetrance of *CDKN2A* mutations varies with

\* Corresponding author: Tel.: +354 525 3600; fax: +354 525 3608.

E-mail address: [thorunnr@uvs.is](mailto:thorunnr@uvs.is) (T. Rafnar).

0959-8049/\$ - see front matter © 2006 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2005.11.029

CMM population incidence rates, suggesting that other factors that affect population incidence of melanoma may also affect *CDKN2A* penetrance.<sup>10</sup> Studies in several populations have found an increased incidence of *CDKN2A* mutations in patients with more than one primary melanoma but no family history of the disease.<sup>11–14</sup> Some families with a mutation in *CDKN2A* also have an increased risk of pancreatic cancer but other risk factors are likely to play a role as well.<sup>8</sup> Recently, a susceptibility locus for melanoma on chromosome 1p22 was identified in 49 Australian pedigrees.<sup>15,16</sup>

Epidemiological studies have shown that a high density of dysplastic nevi, light skin, hair and eye colour are also risk factors for CMM.<sup>17</sup> Polymorphisms in the Melanocortin-1 receptor (MC1R) have been associated with hair colour and skin type and seem to affect the risk of radiation sensitivity and CMM.<sup>18</sup> MC1R variants also influence the penetrance of *CDKN2A* mutations.<sup>19</sup>

Similar to other northern-European populations, CMM incidence has increased rapidly in Iceland in the last decades.<sup>20</sup> During the period 1998–2002, the age-standardized incidence was 9/100,000 for males and 18.5/100,000 for females and had tripled from the incidence observed around 1980 (Annual report of the Icelandic Cancer Registry).<sup>21</sup> Currently, melanoma is the 11th most common malignancy in Iceland. Limited information exists about the genetics of melanoma in Iceland. Several families have been observed that have more than one case of melanoma or one case of melanoma and one case of pancreatic cancer or glioma. A study of 12 of these families failed to identify any germ-line *CDKN2A* mutations.<sup>22</sup> Finally, a population-based study of the familial nature of all cancers in Iceland included data that suggested significant familial aggregation of CMM.<sup>23</sup>

The aim of the present study was to use the population-based Cancer Registry in Iceland to estimate the cancer risk of family members of CMM patients and determine if families with high risk of melanoma are found in the population that might be useful in the search for new genes that predispose to melanoma.

## 2. Patients and methods

All individuals in Iceland diagnosed with CMM (ICD7 190) during a 45-year interval (1955–1999) were included in the study. The Genetical Committee of the University of Iceland traced the families of the probands up to third-degree relatives (first-degree relatives include parents, siblings, and offspring). The committee's data was based on the National Population Registry (NPR), which has been in operation since 1952, and provides every permanent resident of Iceland with a unique identification number. Until the establishment of NPR, birth, death, church and marriage records formed the basis of the Genetical Committee's data, which traces pedigrees of individuals as far back as 1840.

The Icelandic Cancer Registry (ICR) provided information on cancer in relatives. The ICR has been in operation since 1954,<sup>24</sup> covers the entire population of Iceland and determines incidence of cancer by site. The registry receives information from all pathology and cytology laboratories in Iceland, in addition to hematology laboratories, hospital wards, private medical practitioners and other individual

health care workers.<sup>25</sup> Approximately 94.5% of diagnoses in the ICR have histological confirmation.<sup>25</sup> The population-based cancer registration and the follow-up of individuals, is made possible by the NPR. In the period 1961–2000, immigration ranged between 0.07% and 1.05% per annual population, emigration ranged between 0.17% and 1.33%, and the net change ranged between 0.02% and 0.67%.<sup>26–28</sup> When calculating person-years at risk, individuals were considered at risk from birth or from the year 1955, whichever came later, until diagnosis of the cancer in question, death, or the end of the year 1999, whichever came first. Immigration/emigration was not controlled for. However, given the small percentage of immigration/emigration during the research period, the effects can be considered negligible.

Calendar year from 1955 up to and including 1999 and patient age were used as stratification variables when calculating person-years. Both variables were defined by 5-year strata. The risk of cancer was estimated as the ratio between the observed and expected number of cases (standardized incidence ratio, SIR). The SIR compares the observed number of cases in a cohort with an expected number obtained by applying calendar- and age-specific standard rates to the cohort age structure.<sup>29</sup> The SIRs were estimated separately for males and females.

Two-sided confidence intervals (CI) were calculated assuming a Poisson distribution.<sup>29</sup> Since the confidence intervals were always 95%, one interval out of 20 is expected to exclude 1.00 by chance. Since the data obtained was centralized and population-based, complete ascertainment of cases was accounted for. All CMM cases were counted as both probands and relatives. However, each individual was counted only once when counting observed number of cases, thus avoiding inflating the estimates of the SIRs. The confidence intervals were calculated based on the assumption of independence. Since some individuals came from the same families, the assumption of independence leads to narrower confidence intervals. All data analysis was done using the statistical system R.<sup>30</sup>

## 3. Results

A total of 497 (166 males and 331 females) individuals were diagnosed with CMM in Iceland during 1955–1999. The mean age at diagnosis was 57.5 for males and 51.7 for females (Table 1). Seven probands had more than one diagnosis of primary CMM; their mean age at first diagnosis was 44.3 (95%CI 30.23–58.34, range 31–62). None of the probands with more than one diagnosis of CMM had either a first or second-degree relative with the disease. Examination of the families of these probands revealed no significant history of cancer except in two families; in one family there were several cases of cutaneous melanoma *in situ* on the same side of the family and the other family had two family members with kidney cancer. Eight probands had a first-degree relative with CMM, divided into four families. These individuals did not have a second or a third-degree relative with the disease. The mean age at diagnosis of melanoma among the eight probands who had a first-degree relative with the disease was 59 years (95%CI 42.97–75.03, range 26–86 years). Twenty-two probands had a second-degree relative with melanoma, the mean age at diagnosis was 50.5 (95%CI 42.92–62.03, range 15–83). Finally, four

Download English Version:

<https://daneshyari.com/en/article/2126345>

Download Persian Version:

<https://daneshyari.com/article/2126345>

[Daneshyari.com](https://daneshyari.com)